Top

Published in:

01-11-2004 | Original Article

Dendritic cells reduce number and function of CD4⁺CD25⁺ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma

Authors: Jan Schmidt, Sven Eisold, Markus W. Büchler, Angela Märten

Published in: Cancer Immunology, Immunotherapy | Issue 11/2004

Abstract

Aim and background: CD4⁺CD25⁺ cells are described as professional regulatory/suppressor T cells that are crucial for the prevention of spontaneous autoimmune diseases. They play an important role in maintaining a balanced peripheral immune system. On the other hand, it has been suggested that regulatory T cells (Treg) suppress antitumor immune responses after tumor-specific vaccinations. Therefore, we determined the percentage of regulatory T cells in cytokine-induced killer (CIK) cells, an effector cell population with high impact for adoptive immunotherapeutic strategies. Results: CIK cells showed strong induction of CD4⁺CD25⁺ cells with high secretion of interleukin 10 (IL-10) after unspecific stimulation of the TCR complex and stimulation with interleukin 2. Depletion of CD25⁺ cells led to an increase in cytotoxic activity and a reduction of IL-10 release. A more pronounced reversal of suppression could be induced by coculture of CIK cells with dendritic cells (DCs). After coculture of CIK cells with DCs, the number of CD4⁺CD25⁺ cells as well as the IL-10 concentration in the supernatant decreased, and the cytotoxic activity against pancreatic carcinoma cells increased. This was shown for cells from healthy donors as well as for cells from patients with pancreatic carcinoma. Conclusion: Our established effector cells possess some regulatory features induced by unspecific TCR-activation that could be prevented by coculture with DCs. CIK cells have desirable properties for immunotherapeutical approaches, especially after coculture with DCs, which could be used additionally for induction of a specific immune response.

Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS (2001) Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97:2923PubMed

Barthlott T, Kassiotis G, Stockinger B (2003) T cell regulation as a side effect of homeostasis and competition. J Exp Med 197:451CrossRefPubMed

Bluestone J, Abbas A (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253CrossRefPubMed

Chen FX, Liu JQ, Zhang NZ, Gong XJ, Zhang GL, Xu YM, Zhou ZH, Wang T, Huang J (2002) Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor. Ai Zheng 21:797PubMed

Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193:1303CrossRefPubMed

Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25:243CrossRefPubMed

Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M (2002) Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol Immunother 51:440PubMed

Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621CrossRefPubMed

Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712CrossRefPubMed

10.

Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S (2003) Generation of CD3+CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 77:175PubMed

11.

Linn YC, Lau LC, Hui KM (2002) Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116:78CrossRefPubMed

12.

Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756PubMed

13.

Lu P, Negrin R (1994) A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 153:1687PubMed

14.

Mahnke K, Qian Y, Knop J, Enk AH (2003) Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 23:23

15.

Märten A, Greten T, Ziske C, Renoth S, Schöttker B, Buttgereit P, Schakowski F, von Rücker A, Scheffold C, Sauerbruch T, Schmidt-Wolf I (2002) Generation of activated and antigen-specific T lymphocytes with cytotoxic activity after co-culture with antigen-pulsed dendritic cells. Cancer Immunol Immunother 51:25CrossRefPubMed

16.

Märten A, Renoth S, von Lilienfeld-Toal M, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, Schmidt-Wolf I (2001) Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after coculture with idiotype-pulsed dendritic cells. Haematoligica 86:1029

17.

Märten A, Schöttker B, Ziske C, Weineck S, Buttgereit P, Huhn D, Sauerbruch T, Schmidt-Wolf I (2000) Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9-protein. J Immunother 23:464PubMed

18.

Märten A, Ziske C, Schöttker B, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Scheffold C, Sauerbruch T, Schmidt-Wolf I (2001) Interactions between dendritic cells and NK-like T cells leads to an activation of both populations. J Immunother 24:502CrossRefPubMed

19.

Martin E, O’Sullivan B, Low P, Thomas R (2003) Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18:155CrossRefPubMed

20.

Morse MA, Clay TM, Mosca P, Lyerly HK (2002) Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther 2:827PubMed

21.

Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033CrossRefPubMed

22.

Scheffold C, Brandt K, Johnston V, Lefterova P, Huhn D, Neubauer A, Negrin R, Schmidt-Wolf I (1995) Potential of autologous cytokine induced killer cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 15:33PubMed

23.

Schmidt-Wolf G, Negrin R, Schmidt-Wolf I (1997) Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74:51PubMed

24.

Schmidt-Wolf I, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft H, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D (1999) Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81:1009PubMed

25.

Schmidt-Wolf I, Lefterova P, Johnston V, Neubauer A, Huhn D, Negrin R, Blume K (1994) Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 87:453

26.

Schmidt-Wolf I, Lefterova P, Mehta B, Fernandez L, Huhn D, Blume K, Weissman I, Negrin R (1993) Phenotypic characterization and identification of effector cells involved in tumor recognition of cytokine induced killer cells. Exp Hematol 21:1673PubMed

27.

Schmidt-Wolf I, Negrin R, Kiem H, Blume K, Weissman I (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174:139PubMed

28.

Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81:1009PubMed

29.

Verneris MR, Baker J, Edinger M, Negrin RS (2002) Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice. J Clin Immunol 22:131CrossRefPubMed

30.

Wang FS, Liu MX, Zhang B, Shi M, Lei ZY, Sun WB, Du QY, Chen JM (2002) Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8:464PubMed

31.

Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606PubMed

32.

Wood GW, Holladay FP, Turner T, Wang YY, Chiga M (2000) A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 48:113CrossRefPubMed

Title: Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma
Authors: Jan Schmidt
Sven Eisold
Markus W. Büchler
Angela Märten
Publication date: 01-11-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0554-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

Lower percentages of monocytes with CD80, CD86 and HLA-DR molecule expression in pediatric cancer

Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation?

Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following “suicide” gene therapy in a murine colon carcinoma model

Anti-idiotype responses abrogate anti-CD4–induced tolerance to a tumor-specific antigen and promote systemic tumor immunity

Cancer gene therapy: new horizons in the East

Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: effects on survival time, tumor growth, and tumor neovascularization

Keynote webinar | Spotlight on antibody–drug conjugates in cancer